Clinical trials: Drug Eluting Stents
PAD
VISION and VQI Paclitaxel Safety Analysis
Objectives 1. The VQI-VISION Paclitaxel Device Safety Analysis seeks to assess the comparative safety of paclitaxel-coated balloons and stents in the treatment of PAD through analysis of the Vascular Quality Initiative (VQI)…
- Trial name
- VISION-VQI (NCT04204564)
- Testing
- pactlitaxel PAD device
- Volunteers
- 20,000 people
- Sponsor
- University of Vermont Medical Center
PCI Patients, de Novo Coronary Lesions
iLITE, Clinical Performance of the Angiolite™ Drug-Eluting Stent
Prospective, multi-center, all comers, post market clinical follow-up (PMCF) registry.
- Conditions
- PCI Patients, de Novo Coronary Lesions, Restenotic Coronary Lesions, Acute Myocardial Infarction (AMI)
- Trial name
- iLITE (NCT07887230)
- Testing
- Percutaneous Coronary Intervention
- Volunteers
- 5,000 people
- Sponsor
- iVascular S.L.U.
Peripheral Arterial Disease
Drug Eluting Stent for the Management of PERipheral Arterial Disease Of the SFA (DESPERADO-SFA Study)
This is a prospective, nonrandomized, single-arm study using the Zilver PTXTM stent in patients with Superficial Femoral Artery (SFA) disease (total occlusions or significant stenosis).
- Trial name
- DESPERADO (NCT02734836)
- Testing
- Balloon Angioplasty, Optical Coherence Tomography
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Arkansas Heart Hospital
Intracranial Atherosclerotic Stenosis
Standardized Procedure for Intracranial Drug-Eluting Stenting in the Treatment of Intracranial Atherosclerotic Stenosis
The primary objective of this trial is to evaluate the Safety, Efficacy, and Standardized Procedural Optimization of the Intracranial Drug-Eluting Stent System in Patients with Symptomatic Intracranial Atherosclerotic Stenosis.
- Trial name
- NCT06857058
- Testing
- NOVA DES
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Ischemic Heart Disease, Angina Pectoris
XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE PRIME SV Japan PMS)
The objective of the study is to evaluate the safety and efficacy of XIENCE PRIME SV in real world practice in Japanese hospitals.
- Conditions
- Ischemic Heart Disease, Angina Pectoris, Coronary Artery Disease, Coronary Artery Occlusion
- Trial name
- NCT02513719
- Testing
- XIENCE PRIME SV Everolimus Eluting Coronary Stent
- Where
- 33 sites in Japan
- Volunteers
- 312 people
- Sponsor
- Abbott Medical Devices
Cardiovascular Diseases
Drug Eluting Balloon Efficacy for Small Coronary Vessel Disease Treatment
This is a prospective, multicentre, randomized clinical study of consecutive patients with coronary artery disease in vessels with diameter ≤2.75 mm.
- Trial name
- PICCOLETO II (NCT03899818)
- Testing
- drug-eluting balloon, drug-eluting stent
- Volunteers
- 240 people
- Sponsor
- Fatebenefratelli and Ophthalmic Hospital
Peripheral Artery Disease
Zilver® PTX® in China
The objective of this study is to evaluate the Zilver® PTX® Drug-Eluting Peripheral Stent for treatment of lesions of the above-the-knee femoropopliteal artery in a Chinese patient population.
- Trial name
- NCT02171962
- Testing
- Zilver® PTX® Drug-Eluting Peripheral Stent
- Where
- 9 sites in China
- Volunteers
- 178 people
- Sponsor
- Cook Group Incorporated
Coronary Artery Disease, Bifurcation Lesion
Yao Strategy for the Treatment of de Novo Medina 0,1,0 or 0,0,1 Bifurcation Lesion
Percutaneous coronary intervention for coronary bifurcation lesions represents one of the most challenging procedures in interventional cardiology because of lower angiographic success rate and increased risk of procedural…
- Trial name
- NCT06166459
- Testing
- Drug-coated balloon combined with provisional drug-eluting stent implantation
- Volunteers
- 200 people
- Sponsor
- Xuzhou Third People's Hospital
Coronary Arterial Disease (CAD)
Clinical Investigation for Everolimus Drug Eluting Stent
History of Device Development and Study Rationale: Drug-eluting stents (DES) revolutionized percutaneous coronary intervention (PCI) by significantly reducing restenosis and the need for repeat procedures compared to bare-metal…
- Trial name
- EverGreen (NCT06769217)
- Testing
- Drug Eluting Coronary Stent
- Where
- 5 sites in India, Indonesia
- Volunteers
- 888 people
- Sponsor
- Frisch Medical Device Private Limited
Peripheral Arterial Disease
Post-Market Study of ZENFLEX Pro Stent for Femoropopliteal Artery Lesions
This is a prospective, multi-center, single-arm post-market study evaluating the safety and effectiveness of the ZENFLEX Pro™ Drug-eluting Stent in treating femoropopliteal artery stenosis or occlusion.
- Trial name
- NCT07049120
- Testing
- ZENFLEX Pro™ Peripheral Drug-eluting Stent System
- Where
- Poland
- Volunteers
- 153 people
- Sponsor
- Zhejiang Zylox Medical Device Co., Ltd.
Coronary Disease, Coronary Stenosis
Limus Eluted From A Durable Versus ERodable Stent Coating
The purpose of this study is to compare the BioMatrix Flex (Biolimus A9-Eluting) stent system with the Cypher SELECT (Sirolimus-Eluting) stent system in a non-inferiority trial.
- Trial name
- LEADERS (NCT00389220)
- Testing
- Coronary stent placement
- Where
- 10 sites in Belgium, France and 5 more
- Volunteers
- 1,707 people
- Sponsor
- Biosensors Europe SA
Coronary Artery Disease, Drug-eluting Stents
Kor PCI - CAD Patients Treated With PCI: Analysis of the Korean Nationwide Health Insurance Database
Current Status and Prognosis of Coronary artery disease patients treated with coronary intervention - Analysis of the Korean Nationwide Health Insurance Database
- Conditions
- Coronary Artery Disease, Drug-eluting Stents, Drug-coated Balloon
- Trial name
- NCT04778969
- Testing
- drug-eluting stent, drug-coated balloon
- Volunteers
- 200,000 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease, Coronary Disease
Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions
Percutaneous recanalization of total coronary occlusions (TCO) was historically hampered by high rates of restenosis and reocclusion.
- Conditions
- Coronary Artery Disease, Coronary Disease, Coronary Stenosis
- Trial name
- PRISON-IV (NCT01516723)
- Testing
- Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)
- Where
- 4 sites in Belgium, Netherlands
- Volunteers
- 330 people
- Sponsor
- R&D Cardiologie
Angioplasty, Transluminal, Percutaneous Coronary, Coronary Restenosis
Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial
To evaluate the effect of celecoxib use for 3 month after drug-eluting stent implantation on restenosis on clinical outcome such as target lesion revascularization, thrombotic event, myocardial infarction, death on inflammatory…
- Trial name
- mini-COREA (NCT00500279)
- Testing
- Celecoxib
- Where
- 2 sites in South Korea
- Volunteers
- 900 people
- Sponsor
- Seoul National University Hospital
Coronary Restenosis
SELUTION SLR™ 014 In-stent Restenosis
Prospective, multi-center, randomized, single blind, controlled, noninferiority clinical trial. Subjects with previous bare-metal stent (BMS) or Drug-Eluting Stent (DES) and qualifying evidence for In-stent Restenosis (ISR) will…
- Trial name
- SELUTION4ISR (NCT04280029)
- Testing
- SELUTION SLR 014 DEB, Standard of Care
- Where
- 48 sites in United States, Belgium and 5 more
- Volunteers
- 418 people
- Sponsor
- M.A. Med Alliance S.A.
Coronary Artery Disease
BIOFLOW-INDIA Safety and Clinical PerFormance of the Drug Eluting ORSIRO Stent in Single de Novo Coronary Artery Lesions
The objective of this clinical investigation is to assess the safety and clinical performance of the Orsiro Limus Eluting Stent System in Indian subjects with single de-novo coronary artery lesions.
- Trial name
- NCT01426139
- Testing
- Percutaneous Coronary Intervention Biotronik Orsiro DES
- Where
- 4 sites in India
- Volunteers
- 120 people
- Sponsor
- Biotronik AG
High Ischemic Risk
24-month Ticagrelor-based Dual-antiplatelet Therapy Versus Clopidogrel-based Dual-antiplatelet theRapy aftEr 12 Months of DrUg-eluting Stent Implantation in High isChEmic Risk Patients: P-REDUCE Trial
The purpose of this prospective randomized clinical trial is to compare the clinical outcomes between aspirin with ticagrelor versus aspirin with clopidogrel in high ischemic risk patients beyond 12 months after percutaneous…
- Trial name
- NCT04989257
- Testing
- Ticagrelor-based dual-antiplatelet therapy, Clopidogrel-based dual-antiplatelet therapy
- Where
- South Korea
- Volunteers
- 3,488 people
- Sponsor
- Yonsei University
Angioplasty, Transluminal, Percutaneous Coronary, Percutaneous Coronary Intervention
To Achieve an Early Reendothelialization at the Expense of Low Restenosis: The EREMUS Study
The investigators sought to discover which one of the following strategies is the safest for patients undergoing percutaneous coronary intervention: paclitaxel-coated balloon+Genous stent; Genous stent; drug eluting stent…
- Trial name
- EREMUS (NCT00870038)
- Testing
- Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent, Percutaneous coronary intervention: Uncoated balloon + Genous stent, Percutaneous coronary intervention: Drug eluting stent (Taxus stent)
- Where
- Italy
- Volunteers
- 75 people
- Sponsor
- Ospedale della Misericordia
Coronary Artery Diseases
NOYA CoCr Biodegradable Coating Sirolimus-Eluting Coronary Stent System
A single blind, multi-center, randomized study is preformed to compare NOYA CoCr biodegradable coating sirolimus-eluting stents with Firebird2 drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.
- Trial name
- NCT01226355
- Testing
- stent
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Medfavour (Beijing) Medical Co., Ltd
Coronary Artery Disease
Single Long vs Two Short Overlapping Bioabsorbable Polymer DES
Multiple overlapping drug-eluting coronary stents (DES) are usually needed to treat long coronary stenoses but this strategy is expensive and the response to overlapping DES has not been extensively studied.
- Trial name
- ROCCO (NCT01718106)
- Testing
- implantation of a bioabsorbable polymer DES
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita